Here’s what you should know:
1. Despite a 19.7 percent year-over-year increase, the company’s revenues were lower than Zacks’ estimated $68.5 million.
2. Ironwood reported adjusted losses of $0.28 per share. The losses were higher than Zacks’ estimated $0.23 per share.
3. Ironwood’s key product Linzess generated $167.8 million in sales. As per an agreement, Ironwood splits Linzess sales with Allergan. Ironwood’s net profits from Linzess amounted to $43.8 million.
4. Linzess prescriptions increased 15 percent in the second quarter, surpassing 750,000.
More articles on gastroenterology:
Nevada Supreme Court overturns 2nd-degree murder conviction against gastroenterologist linked to Las Vegas hepatitis C outbreak — 4 insights
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Renewed interest in gastroparesis research brings cure into focus — 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.